PDX1 and pancreatic neoplasm: In this study, a novel RNAi effector platform targeting PDX-1 was developed and studied in human and mouse cell lines, as well as in mouse models of pancreatic cancer, insulinoma and islet neoplasia to determine whether PDX-1 is a potential therapeutic target for control of both hormonal symptoms and tumor volume in these pancreatic diseases.